Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q2 EPS by 10c

Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q2 EPS of $0.20, $0.10 better than the analyst estimate of $0.10. Revenue for the quarter came in at $32.5 million versus the consensus estimate of $33.4 million.

For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c